Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer

Required: BRCA1 germline deleterious mutation

other epithelial non mucinous and non-clear cell ovarian cancer in a patient with germline BRCA 1 or 2 deleterious mutation

Required: BRCA2 germline deleterious mutation

other epithelial non mucinous and non-clear cell ovarian cancer in a patient with germline BRCA 1 or 2 deleterious mutation

Must have received: platinum-based chemotherapy (carboplatin) — frontline

Patient must have received one cycle of carboplatin AUC 5-6 + paclitaxel 175 mg/m²

Must have received: taxane (paclitaxel) — frontline

Patient must have received one cycle of carboplatin AUC 5-6 + paclitaxel 175 mg/m²

Must have received: surgery — frontline, complete cytoreductive surgery (no visible residual disease)

Patient having undergone frontline, complete cytoreductive surgery (i.e. no visible residual disease)

Cannot have received: PARP inhibitor

Any previous treatment with PARP inhibitor

Cannot have received: radiation therapy

Exception: within 6 weeks prior to study treatment

Patient receiving radiotherapy within 6 weeks prior to study treatment

Cannot have received: allogenic bone marrow transplant

Previous allogenic bone marrow transplant

Cannot have received: other simultaneous chemotherapy drugs

Exception: except during a HIPEC procedure with cisplatin at PDS

Administration of other simultaneous chemotherapy drugs - except during a HIPEC procedure with cisplatin at PDS, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period (hormonal replacement therapy is permitted as are steroid antiemetics)